The company has not filed an annual or quarterly report since its Q1 FY2019 10-Q, filed May 10, 2019. Its latest SEC filing is a SC 13G/A from Feb 14, 2020.
10-Q for Q1 FY2019, filed May 10, 2019
The sections below describe the company as of the FY2018 annual report.
Develops gene therapy treatments for patients with rare inherited retinal diseases that can lead to blindness.
10-K for FY2018, filed Mar 18, 2019We are a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients…View ↗
Our second product candidate, NSR-RPGR, is in Phase 2/3 clinical development for the treatment of X-linked retinitis pigmentosa, or XLRP…View ↗
PROGRAM INDICATION STAGE OF DEVELOPMENT NSR-REP1 Choroideremia Phase 3 STAR trial NSR-RPGR X-linked Retinitis Pigmentosa Phase 2/3 XIRIUS…View ↗
No revenue was reported.
10-K for FY2018, filed Mar 18, 2019
10-Q for Q1 FY2019, filed May 9, 2019
−$16.4MView ↗
8-K, filed Jun 10, 2019
On June 7, 2019 (the “Effective Date”), pursuant to the Implementation Agreement, dated as of March 4, 2019 (the “Implementation…View ↗
Competes with Spark Therapeutics, 4D Molecular Therapeutics, Roche, Biogen, MeiraGTx, Janssen, AGTC, and REGENXBIO
10-K for FY2018, filed Mar 18, 2019Choroideremia: Spark Therapeutics is developing SPK-7001, an AAV-based gene therapy for the treatment of CHM, and is currently conducting…View ↗
Loading...
